Drap has officially declared two medical products as spurious and issued orders for their immediate confiscation. The two drugs identified are Efaston 10mg tablets (Dydrogesterone) and Paracare 60ml suspension (Paracetamol 120mg/5ml). These drugs were found to not contain their active ingredients meaning they cannot deliver the therapeutic effects they claim to have.

The regulatory authority has strongly advised the public to stop using these drugs immediately. Citizens are urged to check if the products they hold match the affected batch numbers and to consult healthcare providers if they experienced any adverse effects after using them.

In its notification, Drap instructed health professionals, hospitals, pharmacies, and supply chains to remain alert. Every entity in the medicine distribution network is expected to scrutinize their stocks and halt movement of suspected batches. Any reports of adverse events associated with these products must be submitted for investigation.

This move follows prior actions by the regulatory body, which earlier this year directed certain pharmaceutical companies to recall substandard medical devices. The recurring pattern of regulation signals increased attention to quality control within the industry.

Declaring medicines spurious and ordering their removal from circulation is a serious step in safeguarding public health. Such measures help prevent treatment failures and protect patients from the harm of ineffective or falsified drugs. The emphasis now must be on improving ongoing surveillance, ensuring stricter inspections, and restoring confidence that medicines in the market meet safety and efficacy standards.